- Email: [email protected]
AS-074 Two-Year Clinical Efficacy of Rosuvastatin Compared with Other Potent Statins in Patients Undergoing Percutaneous Coronary Intervesion with Drug Eluting Stents
Wednesday, April 27, 2011
Other Pharmacologic Agents Pharmacological Treatment Wednesday, April 27, 2011
patients with PATI 2-2.9M, 1 patient had ischemic stroke. In 83 patients with PATI ⬎4M, 1 patient presented late stent thrombosis. This patient was discontinuation of anti-platelet therapy. Conclusion: Low PATI was associated with predicting atherothrombotic events. This study suggested that the platelet aggregation test using light transmission aggregometry was expected to identify high risk group of CAD patients. The monitoring of anti-platelet therapy may significantly improve the clinical outcome in CAD patients undergoing PCI.
5:00 PM ⬃ 6:00 PM (Abstracts Nos. AS-023, AS-025, AS-074) AS-023 Usefulness of the Platelet Aggregately Index in Predicting Atherothrombotic Event in Patient Undergoing Coronary Intervention. Yoshiki Nagata, Keisuke Kurokawa, Jyunichiro Inomata, Isao Aburatani, Michiro Maruyama, Kazuo Usuda. Toyama Prefectural Central Hospital, Toyama, Japan. Background: Dual anti-platelet therapy (aspirin, clopidogrel) in patients undergoing percutaneous coronary intervention (PCI) has reduced the rate of major adverse cardiac events. However, not all patients benefit to the same extent from these improvements in antiplatelet therapy. The individual response to anti-platelet therapy is not uniform. Numerous reports have demonstrated that a lower-degree platelet inhibition is a major precipitating factor. Recently, the platelet aggregation test has been applied to monitoring of anti-platelet therapy and its usefulness has been emphasized. Methods: We studied the usefulness of on-treatment platelet reactivity for predicting atherothrombotic complications in patients undergoing coronary intervention. The subjects were 109 coronary artery disease (CAD) patients taking clopidogrel. ADP-induced platelet aggregation test was measured by optical aggregometer and evaluated the platelet aggregately index (PATI). We studied the atherothrombotic events during average 16 months (3 to 28 months).
AS-025 Impact of Bolus Administration of Ascorbic Acid to Prevent Contrast Induced Nephropathy Undergoing Emergent Cardiovascular Procedure. Kota Komiyama, Tamotsu Tejima, Yasuhiro Tanabe, Sakurada Harumizu. Tokyo Metropolitan Hiroo Hospital, Tokyo, Japan. Background: Contrast induced nephropathy (CIN) has been associated with increased in-hospital and long-term morbidity, mortality, and extended hospitalization. It’s very difficult to prevent CIN in emergency, because conventional methods of preventing CIN are more time consuming. Whether bolus administration of Ascorbic Acid which has strong antioxygenation undergoing emergent cardiovascular procedures is effective to prevent CIN is unknown. Methods: Patients who scheduled for emergent cardiovascular procedures were prospectively/randomaizedly enrolled. Enrolled 70 patients (35 patients assigned to ascorbic acid group. 35 patients to standard hydration group) were evaluated. In standard hydration group, 0.9% saline was given total 1500-2500mL. Ascorbic acid group was given 3g bolus administration before the procedure, 2g div after, and 2g div 12 hours after, added to the standard hydration. CIN was defined by an absolute increase of serum creatinine ⱖ0.5mg/dL or ⱖ25% relative increase. Results: There was no significant difference in baseline characteristics between Ascorbic acid group and standard hydration group. All patients did not develop the adverse effect by administered in large quantities of Ascorbic acid. CIN occurred 3 patients (9%) in ascorbic acid group, and 12 patients (34%) in standard hydration group. Conclusion: Bolus administration of ascorbic acid can more effectively prevent CIN than standard hydration (p⬍0.01) and can improve clinical outcomes in patients undergoing emergent cardiovascular procedures.
AS-074 Two-Year Clinical Efficacy of Rosuvastatin Compared with Other Potent Statins in Patients Undergoing Percutaneous Coronary Intervesion with Drug Eluting Stents. Ji Young Park1, Seung-Woon Rha2, Kanhaiya L. Poddar2, Meera Kumari2, Byoung Geol Choi2, Yun Kyung Kim2, Jin Oh Na2, Cheol Ung Choi2, Hong Euy Lim2, Jin Won Kim2, Eung Ju Kim2, Chang Gyu Park2, Hong Seog Seo2, Dong Joo Oh2. 1Eulji General Hospital, Seoul, Korea (Republic of); 2Korean University Guro Hospital, Seoul, Korea (Republic of).
Results: In 3 patients with PATI ⬍0.5M, 1 patient had sudden cardiac death and 1 patient presented subacute stent thrombosis. In 5
Background: High dose potent statin is known to be effective in reducing major adverse cardiovascular events (MACE) among patients (pts) undergoing percutaneous coronary intervention (PCI) with drug-
The American Journal of Cardiology姞 APRIL 27–29, 2011 ANGIOPLASTY SUMMIT ABSTRACTS/Oral
29A
O R A L A B S T R A C T S
Wednesday, April 27, 2011
O R A L A B S T R A C T S
eluting stents (DESs). We evaluated whether the rosuvastatin, so called superstatin can be associated with better long-term clinical outcomes compared with other potent statins in Asian population. Methods: The study population consisted of 998 consecutive patients (pts) undergoing PCI with DESs from November 2005 to June 2008. Angiographic outcomes at 6 months and cumulative clinical outcomes up to 2 years were compared between rosuvastatin group (n⫽ 469 pts, 47.0%) and other statin group (n⫽528 pts, 58.0%) including atorvastatin (n⫽280 pts) and pitavastatin (n⫽248 pts). Results: Both groups had similar baseline clinical and procedural characteristics. Six-month angiographic outcomes showed that rosuvastatin group had lower mean restenosis percent (%) but had similar incidence of binary stenosis and late loss as compared with the other statin group. Major clinical outcomes were similar between the two groups up to 2 years including cardiac death, Q wave MI, repeat PCI and TVR MACE (Table).
30A
Six-month Angiographic and 2-year clinical outcomes
Conclusion: Although rosuvastatin administration was associated with lower restenosis percent (%), this angiographic benefit was not translated into better clinical outcomes compared with other potent statin group up to 2 years.
The American Journal of Cardiology姞 APRIL 27–29, 2011 ANGIOPLASTY SUMMIT ABSTRACTS/Oral
Other Pharmacologic Agents Pharmacological Treatment Wednesday, April 27, 2011
patients with PATI 2-2.9M, 1 patient had ischemic stroke. In 83 patients with PATI ⬎4M, 1 patient presented late stent thrombosis. This patient was discontinuation of anti-platelet therapy. Conclusion: Low PATI was associated with predicting atherothrombotic events. This study suggested that the platelet aggregation test using light transmission aggregometry was expected to identify high risk group of CAD patients. The monitoring of anti-platelet therapy may significantly improve the clinical outcome in CAD patients undergoing PCI.
5:00 PM ⬃ 6:00 PM (Abstracts Nos. AS-023, AS-025, AS-074) AS-023 Usefulness of the Platelet Aggregately Index in Predicting Atherothrombotic Event in Patient Undergoing Coronary Intervention. Yoshiki Nagata, Keisuke Kurokawa, Jyunichiro Inomata, Isao Aburatani, Michiro Maruyama, Kazuo Usuda. Toyama Prefectural Central Hospital, Toyama, Japan. Background: Dual anti-platelet therapy (aspirin, clopidogrel) in patients undergoing percutaneous coronary intervention (PCI) has reduced the rate of major adverse cardiac events. However, not all patients benefit to the same extent from these improvements in antiplatelet therapy. The individual response to anti-platelet therapy is not uniform. Numerous reports have demonstrated that a lower-degree platelet inhibition is a major precipitating factor. Recently, the platelet aggregation test has been applied to monitoring of anti-platelet therapy and its usefulness has been emphasized. Methods: We studied the usefulness of on-treatment platelet reactivity for predicting atherothrombotic complications in patients undergoing coronary intervention. The subjects were 109 coronary artery disease (CAD) patients taking clopidogrel. ADP-induced platelet aggregation test was measured by optical aggregometer and evaluated the platelet aggregately index (PATI). We studied the atherothrombotic events during average 16 months (3 to 28 months).
AS-025 Impact of Bolus Administration of Ascorbic Acid to Prevent Contrast Induced Nephropathy Undergoing Emergent Cardiovascular Procedure. Kota Komiyama, Tamotsu Tejima, Yasuhiro Tanabe, Sakurada Harumizu. Tokyo Metropolitan Hiroo Hospital, Tokyo, Japan. Background: Contrast induced nephropathy (CIN) has been associated with increased in-hospital and long-term morbidity, mortality, and extended hospitalization. It’s very difficult to prevent CIN in emergency, because conventional methods of preventing CIN are more time consuming. Whether bolus administration of Ascorbic Acid which has strong antioxygenation undergoing emergent cardiovascular procedures is effective to prevent CIN is unknown. Methods: Patients who scheduled for emergent cardiovascular procedures were prospectively/randomaizedly enrolled. Enrolled 70 patients (35 patients assigned to ascorbic acid group. 35 patients to standard hydration group) were evaluated. In standard hydration group, 0.9% saline was given total 1500-2500mL. Ascorbic acid group was given 3g bolus administration before the procedure, 2g div after, and 2g div 12 hours after, added to the standard hydration. CIN was defined by an absolute increase of serum creatinine ⱖ0.5mg/dL or ⱖ25% relative increase. Results: There was no significant difference in baseline characteristics between Ascorbic acid group and standard hydration group. All patients did not develop the adverse effect by administered in large quantities of Ascorbic acid. CIN occurred 3 patients (9%) in ascorbic acid group, and 12 patients (34%) in standard hydration group. Conclusion: Bolus administration of ascorbic acid can more effectively prevent CIN than standard hydration (p⬍0.01) and can improve clinical outcomes in patients undergoing emergent cardiovascular procedures.
AS-074 Two-Year Clinical Efficacy of Rosuvastatin Compared with Other Potent Statins in Patients Undergoing Percutaneous Coronary Intervesion with Drug Eluting Stents. Ji Young Park1, Seung-Woon Rha2, Kanhaiya L. Poddar2, Meera Kumari2, Byoung Geol Choi2, Yun Kyung Kim2, Jin Oh Na2, Cheol Ung Choi2, Hong Euy Lim2, Jin Won Kim2, Eung Ju Kim2, Chang Gyu Park2, Hong Seog Seo2, Dong Joo Oh2. 1Eulji General Hospital, Seoul, Korea (Republic of); 2Korean University Guro Hospital, Seoul, Korea (Republic of).
Results: In 3 patients with PATI ⬍0.5M, 1 patient had sudden cardiac death and 1 patient presented subacute stent thrombosis. In 5
Background: High dose potent statin is known to be effective in reducing major adverse cardiovascular events (MACE) among patients (pts) undergoing percutaneous coronary intervention (PCI) with drug-
The American Journal of Cardiology姞 APRIL 27–29, 2011 ANGIOPLASTY SUMMIT ABSTRACTS/Oral
29A
O R A L A B S T R A C T S
Wednesday, April 27, 2011
O R A L A B S T R A C T S
eluting stents (DESs). We evaluated whether the rosuvastatin, so called superstatin can be associated with better long-term clinical outcomes compared with other potent statins in Asian population. Methods: The study population consisted of 998 consecutive patients (pts) undergoing PCI with DESs from November 2005 to June 2008. Angiographic outcomes at 6 months and cumulative clinical outcomes up to 2 years were compared between rosuvastatin group (n⫽ 469 pts, 47.0%) and other statin group (n⫽528 pts, 58.0%) including atorvastatin (n⫽280 pts) and pitavastatin (n⫽248 pts). Results: Both groups had similar baseline clinical and procedural characteristics. Six-month angiographic outcomes showed that rosuvastatin group had lower mean restenosis percent (%) but had similar incidence of binary stenosis and late loss as compared with the other statin group. Major clinical outcomes were similar between the two groups up to 2 years including cardiac death, Q wave MI, repeat PCI and TVR MACE (Table).
30A
Six-month Angiographic and 2-year clinical outcomes
Conclusion: Although rosuvastatin administration was associated with lower restenosis percent (%), this angiographic benefit was not translated into better clinical outcomes compared with other potent statin group up to 2 years.
The American Journal of Cardiology姞 APRIL 27–29, 2011 ANGIOPLASTY SUMMIT ABSTRACTS/Oral